Consensus for FY24 EPS is $4.49. Raises 2024 revenue view to $540M-$560M from $520M-$542M, consensus $554.6M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANIP Upcoming Earnings Report: What to Expect?
- ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
- ANI Pharmaceuticals announces FDA approval, launch of L-Glutamine oral powder
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
- ANI Pharmaceuticals’ Naproxen Delayed-Release Tablets approved by FDA